Literature DB >> 21243402

Synthesis and cytotoxic activities of some 2-arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines.

Yakini Brandy1, Innocent Ononiwu, Dolapo Adedeji, Vonetta Williams, Claudia Mouamba, Yasmine Kanaan, Robert L Copeland, Dwayne A Wright, Ray J Butcher, Samuel R Denmeade, Oladapo Bakare.   

Abstract

The synthesis of five 2-arylnaphtho[2,3-d]oxazole-4,9-dione derivatives was accomplished by refluxing 2-amino-3-bromo-1,4-naphthoquinone with appropriate benzoyl chloride analogs at elevated temperatures. In vitro anticancer evaluation of these compounds was performed on androgen-dependent, LNCaP, and androgen-independent, PC3, human prostate cancer cell lines. In general, these compounds displayed slightly stronger cytotoxicity on the androgen-dependent LNCaP than on the androgen-independent PC3 prostate cancer cell lines. The meta-substituted 2-(3-Chloro-phenyl)-naphtho[2,3-d]oxazole-4,9-dione (10) appear to display the best cytotoxicity on both cell lines with an IC(50) of 0.03 μM on LNCaP and 0.08 μM on PC3 after 5 days of exposure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21243402      PMCID: PMC3756683          DOI: 10.1007/s10637-011-9635-3

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  17 in total

1.  Shikonin derivatives: synthesis and inhibition of human telomerase.

Authors:  Qun Lu; Weijun Liu; Jian Ding; Junchao Cai; Wenhu Duan
Journal:  Bioorg Med Chem Lett       Date:  2002-05-20       Impact factor: 2.823

2.  Synthesis and biological evaluation of novel heterocyclic quinones as inhibitors of the dual specificity protein phosphatase CDC25C.

Authors:  Olivier Lavergne; Anne-Cécile Fernandes; Laetitia Bréhu; Alban Sidhu; Marie-Christine Brézak; Grégoire Prévost; Bernard Ducommun; Marie-Odile Contour-Galcera
Journal:  Bioorg Med Chem Lett       Date:  2005-10-10       Impact factor: 2.823

3.  Synthesis, metabolism and in vitro cytotoxicity studies on novel lavendamycin antitumor agents.

Authors:  Wen Cai; Mary Hassani; Rajesh Karki; Ervin D Walter; Katherine H Koelsch; Hassan Seradj; Jayana P Lineswala; Hamid Mirzaei; Jeremy S York; Fatemeh Olang; Minoo Sedighi; Jennifer S Lucas; Thomas J Eads; Anthony S Rose; Sahba Charkhzarrin; Nicholas G Hermann; Howard D Beall; Mohammad Behforouz
Journal:  Bioorg Med Chem       Date:  2010-01-25       Impact factor: 3.641

4.  Design, synthesis, and biological evaluation of novel naphthoquinone derivatives with CDC25 phosphatase inhibitory activity.

Authors:  Marie-Priscille Brun; Emmanuelle Braud; Delphine Angotti; Odile Mondésert; Muriel Quaranta; Matthieu Montes; Maria Miteva; Nohad Gresh; Bernard Ducommun; Christiane Garbay
Journal:  Bioorg Med Chem       Date:  2005-08-15       Impact factor: 3.641

5.  Synthesis of 7-oxo-7H-naphtho[1,2,3-de]quinoline derivatives as potential anticancer agents active on multidrug resistant cell lines.

Authors:  Maria Dzieduszycka; Maria M Bontemps-Gracz; Barbara Stefańska; Sante Martelli; Agnieszka Piwkowska; Małgorzata Arciemiuk; Edward Borowski
Journal:  Bioorg Med Chem       Date:  2006-02-02       Impact factor: 3.641

6.  Cytotoxicity and apoptosis of benzoquinones: redox cycling, cytochrome c release, and BAD protein expression.

Authors:  Gabriela Tudor; Peter Gutierrez; Angelica Aguilera-Gutierrez; Edward A Sausville
Journal:  Biochem Pharmacol       Date:  2003-04-01       Impact factor: 5.858

Review 7.  Antitumour quinones.

Authors:  C Asche
Journal:  Mini Rev Med Chem       Date:  2005-05       Impact factor: 3.862

8.  NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.

Authors:  Yusheng Han; Hongmei Shen; Brian I Carr; Peter Wipf; John S Lazo; Su-shu Pan
Journal:  J Pharmacol Exp Ther       Date:  2004-01-12       Impact factor: 4.030

9.  Synthesis and MEK1 inhibitory activities of imido-substituted 2-chloro-1,4-naphthoquinones.

Authors:  Oladapo Bakare; Curtis L Ashendel; Hairuo Peng; Leon H Zalkow; Edward M Burgess
Journal:  Bioorg Med Chem       Date:  2003-07-17       Impact factor: 3.641

10.  Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity.

Authors:  Bipul R Acharya; Diptiman Choudhury; Amlan Das; Gopal Chakrabarti
Journal:  Biochemistry       Date:  2009-07-28       Impact factor: 3.162

View more
  4 in total

1.  A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.

Authors:  Oren Levy; W Nathaniel Brennen; Edward Han; David Marc Rosen; Juliet Musabeyezu; Helia Safaee; Sudhir Ranganath; Jessica Ngai; Martina Heinelt; Yuka Milton; Hao Wang; Sachin H Bhagchandani; Nitin Joshi; Neil Bhowmick; Samuel R Denmeade; John T Isaacs; Jeffrey M Karp
Journal:  Biomaterials       Date:  2016-03-17       Impact factor: 12.479

2.  Flavoenzyme-mediated reduction reactions and antitumor activity of nitrogen-containing tetracyclic ortho-quinone compounds and their nitrated derivatives.

Authors:  Milda Peciukaityte-Alksne; Jonas Šarlauskas; Lina Miseviciene; Audrone Maroziene; Narimantas Cenas; Kastis Krikštopaitis; Zita Staniulyte; Žilvinas Anusevicius
Journal:  EXCLI J       Date:  2017-05-11       Impact factor: 4.068

3.  Design, synthesis and biological potential of heterocyclic benzoxazole scaffolds as promising antimicrobial and anticancer agents.

Authors:  Saloni Kakkar; Sanjiv Kumar; Balasubramanian Narasimhan; Siong Meng Lim; Kalavathy Ramasamy; Vasudevan Mani; Syed Adnan Ali Shah
Journal:  Chem Cent J       Date:  2018-09-19       Impact factor: 4.215

4.  Synthesis and characterization of novel unsymmetrical and symmetrical 3-halo- or 3-methoxy-substituted 2-dibenzoylamino-1,4-naphthoquinone derivatives.

Authors:  Yakini Brandy; Nailah Brandy; Emmanuel Akinboye; Malik Lewis; Claudia Mouamba; Seshat Mack; Ray J Butcher; Alan J Anderson; Oladapo Bakare
Journal:  Molecules       Date:  2013-02-04       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.